SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Zmudka Krzysztof)
 

Sökning: WFRF:(Zmudka Krzysztof) > Early abciximab use...

  • Siudak, ZbigniewJagiellonian University (författare)

Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry

  • Artikel/kapitelEngelska2010

Förlag, utgivningsår, omfång ...

  • Polish Cardiac Society / TERMEDIA,2010
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-57391
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-57391URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: Primary percutaneous coronary intervention (PCI) is the preferred method of reperfusion in patients with ST elevation myocardial infarction (STEMI). Abciximab is a well established adjunct to primary PCI. The proper timing of abciximab administration in STEMI patients has been investigated in randomised trials, registries and metanalysis, providing conflicting results. Methods: Consecutive data on STEMI patients, transferred for primary PCI in hospital/ambulance STEMI networks between November 2005 and January 2007, from 15 PCI centres in seven European countries was gathered together for a one-year long-term clinical observation (93% rate of completeness). Results: Data from 1,650 patients was collected in the EUROTRANSFER Registry. Abciximab was administered to 1,086 patients (66%), 727 patients received early (at least 30 minutes prior to first balloon inflation) abciximab (EA), and another 359 patients received late abcixirnab (LA). One year mortality was 5.8% in the EA group vs 10.3% with LA (p = 0.007). Adjustment for propensity score methods for EA administration did not change the results, still providing a favourable outcome for the EA group (p = 0.004). It was also revealed that only a minority of patients (36%) were treated within the 90-minute recommended time window from first medical contact to PCI (and 60% for the 120-min time delay). Conclusions: Patients transferred for primary PCI in STEMI hospital networks showed lower rates of death in long-term one-year clinical follow-up when treatment with abciximab was started early.

Ämnesord och genrebeteckningar

  • myocardial infarction
  • percutaneous coronary intervention
  • abciximab
  • registry
  • MEDICINE
  • MEDICIN

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Rakowski, TomaszJagiellonian University (författare)
  • Dziewierz, ArturJagiellonian University (författare)
  • Janzon, MagnusÖstergötlands Läns Landsting,Linköpings universitet,Kardiologi,Hälsouniversitetet,Kardiologiska kliniken(Swepub:liu)magja75 (författare)
  • Birkemeyer, RalfVillingen Schwenningen, Germany (författare)
  • Stefaniak, JustynaKrakow Cardiovasc Research Institute (författare)
  • Partyka, LukaszKrakow Cardiovasc Research Institute (författare)
  • Zmudka, KrzysztofJagiellonian University (författare)
  • Dudek, DariuszJagiellonian University (författare)
  • Jagiellonian UniversityKardiologi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:KARDIOLOGIA POLSKA: Polish Cardiac Society / TERMEDIA68:5, s. 539-5450022-9032

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy